DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2320079/blueprint-medicines-bpmc-forms-hammer-chart-pattern-time-for-bottom-fishing?cid=CS-ZC-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2320079 Aug 09, 2024 - After losing some value lately, a hammer chart pattern has been formed for Blueprint Medicines (BPMC), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. 0

https://www.zacks.com/stock/news/2318310/masimo-masi-q2-earnings-beat-estimates-gross-margin-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2318310 Aug 07, 2024 - Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results. 0

https://www.zacks.com/stock/news/2315371/blueprint-medicines-bpmc-down-despite-q2-earnings-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2315371 Aug 02, 2024 - Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines. 0

https://www.zacks.com/stock/news/2265333/what-s-in-store-for-dentsply-sirona-xray-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2265333 Apr 30, 2024 - DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds. 0

https://www.zacks.com/stock/news/2263587/factors-setting-the-tone-for-ecolab-s-ecl-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2263587 Apr 26, 2024 - Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength. 0

https://www.zacks.com/stock/news/2227594/here-s-what-key-metrics-tell-us-about-blueprint-medicines-bpmc-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2227594 Feb 16, 2024 - While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2226283 Feb 14, 2024 - Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15. 0

https://www.zacks.com/stock/news/2223454/blueprint-medicines-bpmc-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223454 Feb 08, 2024 - Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2210972/what-makes-blueprint-medicines-bpmc-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2210972 Jan 16, 2024 - Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 0

https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923 Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever. 0